FGFR1OP2 Antibody

What is FGFR1OP2 and why are antibodies against it important in research?

FGFR1OP2 (FGFR1 Oncogene Partner 2) is a protein that may be involved in wound healing pathways . It has a calculated molecular weight of approximately 29 kDa, though it is frequently observed at around 25 kDa in experimental settings . The protein is encoded by the FGFR1OP2 gene (Gene ID: 26127) .

FGFR1OP2 antibodies are crucial research tools because:

• They enable detection and quantification of FGFR1OP2 in various tissues and cell types

• They facilitate investigation of FGFR1OP2's role in normal physiology and pathological conditions

• They are essential for studying FGFR1OP2-FGFR1 fusion proteins implicated in myeloproliferative neoplasms and T-cell lymphomas

• They allow researchers to examine potential therapeutic targets in FGFR1-mediated malignancies

What are the critical specifications to consider when selecting an FGFR1OP2 antibody?

When selecting an FGFR1OP2 antibody for research applications, consider the following technical specifications:

For instance, antibody 11605-1-AP targets FGFR1OP2 in WB, IHC, and ELISA applications and shows reactivity with human, mouse, and rat samples , while ABIN565228 is specific to amino acids 62-169 and is suitable for ELISA and WB in human samples .

What are the recommended dilutions and conditions for FGFR1OP2 antibody applications?

Application-specific dilutions vary by antibody and manufacturer but typically follow these general ranges:

For example, antibody 11605-1-AP is recommended for Western Blot at 1:1000-1:8000 and for IHC at 1:50-1:500 . It is advisable to titrate each reagent in your specific testing system to obtain optimal results, as performance can be sample-dependent .

How can I validate the specificity of an FGFR1OP2 antibody in my experimental system?

Validating antibody specificity is critical for ensuring reliable research data. Implement these methodological approaches:

• Positive and negative controls:

  • Use tissues or cells known to express FGFR1OP2 (e.g., thymus tissue for antibody 11605-1-AP)

  • Include knockout or knockdown models as negative controls (similar to the MCF7 FGFR1 KO cells used in )

• Blocking peptide experiments:

  • Pre-incubate antibody with immunizing peptide/protein

  • Compare staining patterns between blocked and unblocked antibody

• Multiple antibody validation:

  • Use antibodies targeting different epitopes of FGFR1OP2

  • Compare staining patterns and signal intensities

• Orthogonal methods:

  • Correlate protein detection with mRNA expression data

  • Use mass spectrometry for protein identification

• Molecular weight verification:

  • Confirm signal appears at expected molecular weight (calculated: 29 kDa, observed: often 25 kDa)

For instance, researchers validated FGFR1 antibodies using both knockout cell lines and immunoblotting to verify specificity, demonstrating the importance of using multiple validation methods .

How can FGFR1OP2 antibodies be used to study FGFR1OP2-FGFR1 fusion in hematological malignancies?

FGFR1OP2-FGFR1 fusion has been identified in myeloproliferative neoplasms and T-cell lymphomas. Methodological approaches using FGFR1OP2 antibodies include:

• Detection of fusion proteins:

  • Western blot analysis using antibodies targeting the N-terminal region of FGFR1OP2 to detect fusion proteins

  • Comparison with antibodies targeting the C-terminal region of FGFR1

• Tissue localization studies:

  • IHC to examine expression patterns in bone marrow and lymphoid tissues

  • Double staining with lineage markers to identify affected cell populations

• Functional studies:

  • Immunoprecipitation to isolate fusion proteins and associated complexes

  • Phosphorylation-specific antibodies to assess activation status

• Animal model validation:

  • Studies have shown that FGFR1OP2-FGFR1 expression in mouse hematopoietic stem cells leads to myeloproliferative disorder, AML, and T-cell lymphoma

  • Antibodies can help track expression and localization in these models

As demonstrated in research, FGFR1OP2-FGFR1 fusion was isolated from the KG1 cell line and used to develop a representative mouse model showing similar disease progression to human patients, highlighting the utility of these antibodies in translational research .

How do epitope differences affect FGFR1OP2 antibody performance in various applications?

Epitope specificity significantly impacts antibody performance across applications. Consider these methodological implications:

Methodological considerations:

• Native vs. denatured conditions:

  • Some epitopes may only be accessible under native or denatured conditions

  • For example, conformational epitopes may be lost in Western blotting but preserved in immunoprecipitation

• Cross-reactivity assessment:

  • Antibodies targeting highly conserved regions may cross-react with related proteins

  • Evaluate cross-reactivity experimentally or through sequence alignment analysis

• Epitope masking in protein complexes:

  • Protein-protein interactions may obscure antibody binding sites

  • Consider alternative antibodies targeting different epitopes when studying protein complexes

The strategic selection of epitope-specific antibodies is critical for experimental success, particularly when studying protein isoforms, fusion proteins, or specific functional domains.

What are common challenges in detecting FGFR1OP2 in experimental models and how can they be addressed?

Researchers frequently encounter these challenges when working with FGFR1OP2 antibodies:

• Low signal intensity:

  • Optimize antibody concentration through titration experiments

  • Enhance signal using more sensitive detection methods (e.g., amplification systems)

  • Implement antigen retrieval for IHC (e.g., with TE buffer pH 9.0 or citrate buffer pH 6.0 as suggested for antibody 11605-1-AP)

• High background signal:

  • Increase blocking time/concentration

  • Optimize antibody dilution

  • Include additional washing steps

  • Use more specific secondary antibodies

• Cross-reactivity issues:

  • Validate antibody specificity using controls

  • Pre-absorb antibody with potential cross-reactive proteins

  • Select antibodies targeting unique epitopes

• Inconsistent results between applications:

  • Consider antibodies validated for specific applications

  • Adjust protocols based on application requirements

  • Select antibodies targeting epitopes accessible in the specific experimental condition

For example, antibody 11605-1-AP requires specific antigen retrieval conditions for IHC in human intrahepatic cholangiocarcinoma tissue , illustrating the importance of technique-specific optimization.

How do FGFR1OP2 antibodies compare with FGFR1 antibodies for studying FGFR signaling pathways?

When investigating FGFR signaling networks, researchers should consider these methodological differences:

• Target specificity and detection capabilities:

  • FGFR1OP2 antibodies: Detect FGFR1OP2 protein, FGFR1OP2-FGFR1 fusions

  • FGFR1 antibodies: Detect all forms of FGFR1, including fusions with various partners

• Applications in fusion protein research:

  • Concurrent use of both antibody types can distinguish fusion proteins from wild-type proteins

  • FGFR1 antibodies targeting different domains (extracellular, kinase, C-terminal) show varying detection capabilities

• Signal interpretation considerations:

  • Differential expression patterns between FGFR1 and FGFR1OP2

  • FGFR1 shows variable subcellular localization (membrane, cytoplasmic, nuclear)

Research has shown that FGFR1 protein expression does not always correlate with gene amplification in cancer models. In a study of breast cancer samples, only 50% of FGFR1-amplified cases showed strong FGFR1 protein overexpression , highlighting the importance of using both FGFR1 and fusion partner antibodies for comprehensive analysis.

How can FGFR1OP2 antibodies be used in combination with other techniques to study FGFR1 signaling networks?

Integrating multiple methodological approaches enhances research outcomes:

• Multiparametric analysis:

  • Combine immunofluorescence with FGFR1OP2 antibodies and phospho-specific antibodies

  • Assess activation status of downstream signaling pathways (RAF/MAPK/ERK/RSK and PI3K/AKT/PDK/mTOR/S6K)

• Correlation with genomic/transcriptomic data:

  • Integrate protein expression data with RNA-seq

  • Examine relationships between gene amplification and protein expression levels

• Proximity ligation assays:

  • Study protein-protein interactions between FGFR1OP2 and other signaling molecules

  • Visualize spatial relationships in intact cells

• Therapeutic response monitoring:

  • Evaluate changes in FGFR1OP2 expression following treatment with FGFR inhibitors

  • Assess correlation between protein expression and clinical response

Research has demonstrated that FGFR signaling pathways exhibit architectural flexibility, with both shared and divergent responses to FGFR2 inhibition observed in the canonical signaling pathways . Similar approaches could be applied to FGFR1OP2-FGFR1 signaling studies.

What role do FGFR1OP2 antibodies play in understanding paradoxical effects of FGFR signaling in cancer models?

Recent research has identified unexpected effects in FGFR signaling that FGFR1OP2 antibodies can help investigate:

• Paradoxical growth effects:

  • FGF2 treatment can paradoxically decrease proliferation in cells with FGFR1 amplification

  • FGFR1OP2 antibodies can help track expression changes associated with this phenomenon

• Signaling pathway divergence analysis:

  • FGF2-induced effects involve JAK-STAT signaling and p21 modulation

  • Combined use of FGFR1OP2 and pathway-specific antibodies can map these interactions

• Stemness transition monitoring:

  • FGF2 association with stemness signatures in tumors with high FGFR1 expression

  • FGFR1OP2 antibodies can help characterize cell populations undergoing phenotypic shifts

The discovery that FGF2 increases FGFR1 protein levels in FGFR1-amplified cells, correlating with increased p21 levels , demonstrates the importance of antibody-based detection in revealing complex signaling dynamics that have significant implications for FGFR-targeted therapies.

How do commercially available FGFR1OP2 antibodies differ in their performance characteristics?

Several FGFR1OP2 antibodies are available from different manufacturers, each with distinct characteristics:

When selecting between these options, consider:

• Application compatibility: Choose antibodies validated for your specific technique

• Species reactivity: Ensure compatibility with your experimental model

• Epitope specificity: Select based on the protein region of interest

• Clonality: Monoclonal for consistent epitope targeting; polyclonal for broader epitope recognition

For instance, if studying human-mouse comparative models, antibody 11605-1-AP offers cross-species reactivity , while ABIN565228 is limited to human samples .

How are FGFR1OP2 antibodies utilized in cancer research, particularly in relation to FGFR1 amplification and overexpression?

FGFR1OP2 antibodies provide valuable tools for investigating FGFR1-mediated oncogenesis:

• FGFR1OP2-FGFR1 fusion protein detection:

  • Myeloproliferative neoplasms (MPN) associated with FGFR1 translocations represent a distinct disease entity in WHO classification

  • Antibodies enable detection of fusion proteins in patient samples and cell lines

• Expression correlation studies:

  • Compare FGFR1OP2 expression with FGFR1 amplification status

  • Research has shown that only 50% of FGFR1-amplified breast cancer cases show strong protein overexpression

• Therapeutic response prediction:

  • Antibody-based detection of FGFR1OP2-FGFR1 may help predict response to FGFR inhibitors

  • Combined FISH and IHC approaches improve patient selection for clinical trials

• Fusion-specific targeting:

  • Development of therapeutic antibodies targeting fusion proteins

  • Similar to approaches used with other FGFR antibodies that effectively inhibit tumor growth